Subjects
Healthy nonsmoking Chinese male volunteers aged
18 to 40 years with a body mass index (BMI) between
19 and 25 kg/m2 were assessed for inclusion in the study.
As data obtained from women can be influenced by
additional variables such as menstruation and pregnancy,
the guidelines of the Chinese SFDA generally recommend
selecting healthy males for bioequivalence studies.18
Therefore, women were not included in the present study.
Subjects were to have had no significant medical history
or any history of drug abuse. No clinically significant
abnormalities were to be present, as determined by
physical examination, vital signs, and 12-lead ECGs. All
clinical laboratory tests, such as urinalysis, hematology,
and blood chemistry, were required to be normal prior
to enrollment. Serologic tests (hepatitis B surface antigen,
hepatitis C virus antibody, and HIV antibody) needed
to be negative. Anyone who was already participating
in an investigational study, who was using any investigational
drugs, or who had donated ≥200 mL of blood
within 90 days prior to study initiation was excluded.
Subjects were excluded if they had taken any prescription
medication, any traditional Chinese medicine, or
any over-the-counter medication 2 weeks before or during
the study period. Any subjects with a concurrent
illness or with a history of hypersensitivity to atorvastatin
or related compounds were also excluded.